Opendata, web and dolomites

BITCAT SIGNED

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BITCAT project word cloud

Explore the words cloud of the BITCAT project. It provides you a very rough idea of what is the project "BITCAT" about.

inhibition    propagating    area    prolific    polycationic    immunity    proper    utilized    drugs    german    technique    surface    induce    scientific    immunology    suppression    class    practical    ex    isoforms    pd    designed    advantageous    models    career    advantage    checkpoint    cell    renowned    demonstrated    rna    charmingly    antagonistic    tissue    systemic    nanoparticles    advantages    tumour    world    mechanism    protein    escape    society    health    mcmaster    special    polyethylenimine    interests    bioavailability    considerable    vitro    competitive    vivo    cancer    employment    reduce    oncology    immune    successful    efficacy    genes    expression    antisense    either    environment    skipping    mediated    candidates    liposomal    completely    toxicity    anti    therapy    good    fraunhofer    university    modulate    genetics    antibodies    receptor    oligonucleotides    soluble    canadian    arose    immunotherapy    tested    exon    clinical    vaccines    tumours    evading    l1    pto    researcher    potentially    ctla4    block    immunotherapeutics   

Project "BITCAT" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 243˙352 €
 EC max contribution 243˙352 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-05-08   to  2020-05-07

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 243˙352.00
2    MCMASTER UNIVERSITY CA (HAMILTON) partner 0.00

Map

 Project objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity. Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed. To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms. To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution. Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BITCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More  

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

CP-FTmmW Aminogen (2020)

Chemistry and structure of aminogen radicals using chirped-pulse Fourier transform (sub)millimeter rotational spectroscopy

Read More